US pharmaceutical giant Pfizer could make a hostile bid for AstraZeneca as early as today.
Its £63 billion takeover offer was rejected after the UK company said it "substantially" undervalued the business.
That has forced Pfizer to consider its next move, with industry experts believing a hostile bid - which would aim to bypass the AstraZeneca management and target shareholders directly - could come soon.
Last week, Pfizer insisted it was committed to building a research and development hub in Cambridge which was planned by AstraZeneca.
The £300m base at the Cambridge Biomedial Campus would house about 2,000 researchers.
But a hostile bid would trigger increased calls for the offer to be referred to the competition authorities and would also heighten union fears over jobs if the takeover was successful.
More top news
Thousands of rugby fans have been descending on Stadium MK this afternoon for a game between Northampton Saints and Saracens.
A 16-year-old motorcyclist has been seriously hurt after he ran into a rope tied between trees across a path in St Neots
Police have released an E fit after a woman runner was attacked on the riverbank in Nazeing in Essex